Project Number 2R01AG020197-06A2 Agency/Funding Organization NIA Funding Year 2008 View Full Project Details for IMMUNE THERAPY AND IMAGING IN MOUSE AND PRIMATE MODELS OF ALZHEIMER'S DISEASE Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category A. Molecular Pathogenesis and Physiology of Alzheimer's Disease and Alzheimer's Disease-related Dementias (AD/ADRDs) 9. Immunity and Inflammation d. Immunotherapy - Mechanisms of Action Researcher and Organization Principal Investigator SIGURDSSON, EINAR M Principal Investigator First Name EINAR M Principal Investigator Last Name SIGURDSSON Awardee Organization NEW YORK UNIVERSITY SCHOOL OF MEDICINE Awardee State New York, N.Y. Contact PI Country United States Project Detail Funding Opportunity Announcement PA-07-070: RESEARCH PROJECT GRANT (PARENT R01) FY Overall Cost $352,601 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official SNYDER, STEPHEN D. Related Resources Repository [AlzPED] Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy [AlzPED] Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. [AlzPED] Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. [AlzPED] Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging. [AlzPED] Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages. [AlzPED] A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. [AlzPED] Immunization with a Nontoxic/Nonfibrillar Amyloid-β Homologous Peptide Reduces Alzheimer’s Disease- Associated Pathology in Transgenic Mice
